Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001171843-24-006248
Filing Date
2024-11-12
Accepted
2024-11-12 08:01:23
Documents
62
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q cmpx20240930_10q.htm   iXBRL 10-Q 974996
2 EXHIBIT 10.13 ex_741309.htm EX-10.13 904617
3 EXHIBIT 31.1 ex_741168.htm EX-31.1 13730
4 EXHIBIT 32.1 ex_741169.htm EX-32.1 5293
10 exhibita1.jpg GRAPHIC 105082
11 exhibitb.jpg GRAPHIC 133182
  Complete submission text file 0001171843-24-006248.txt   6119097

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA cmpx-20240930.xsd EX-101.SCH 40621
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cmpx-20240930_def.xml EX-101.DEF 275916
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmpx-20240930_lab.xml EX-101.LAB 253801
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmpx-20240930_pre.xml EX-101.PRE 305452
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE cmpx-20240930_cal.xml EX-101.CAL 33724
65 EXTRACTED XBRL INSTANCE DOCUMENT cmpx20240930_10q_htm.xml XML 751906
Mailing Address 80 GUEST STREET BOSTON MA 02135
Business Address 80 GUEST STREET BOSTON MA 02135 617-500-8099
Compass Therapeutics, Inc. (Filer) CIK: 0001738021 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39696 | Film No.: 241443512
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)